Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Carcinoma of lung
|
0.020 | GeneticVariation | BEFREE | To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S). | 26920031 | 2016 | |||||
Neoplasms
|
0.020 | GeneticVariation | BEFREE | Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation. | 27863474 | 2016 | |||||
Carcinoma of lung
|
0.020 | GeneticVariation | BEFREE | Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation. | 27863474 | 2016 | |||||
Neoplasms
|
0.020 | GeneticVariation | BEFREE | One tumor harbored a missense mutation in the c-Kit (p.F504L) and in the KRAS gene (p.G12S). | 21131919 | 2011 | |||||
Malignant neoplasm of lung
|
0.010 | GeneticVariation | BEFREE | To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S). | 26920031 | 2016 | |||||
Primary malignant neoplasm of lung
|
0.010 | GeneticVariation | BEFREE | To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S). | 26920031 | 2016 | |||||
melanoma
|
0.010 | GeneticVariation | BEFREE | Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation. | 27863474 | 2016 | |||||
Split hand foot deformity 1
|
0.010 | GeneticVariation | BEFREE | There was 100% concordance between tissue and urinary cfDNA genotype in treatment-naïve samples. cfDNA analysis facilitated identification of previously undescribed KRAS(G12S)-mutant ECD and dynamically tracked disease burden in patients treated with a variety of therapies. | 25324352 | 2015 | |||||
Endocardial Cushion Defects
|
0.010 | GeneticVariation | BEFREE | There was 100% concordance between tissue and urinary cfDNA genotype in treatment-naïve samples. cfDNA analysis facilitated identification of previously undescribed KRAS(G12S)-mutant ECD and dynamically tracked disease burden in patients treated with a variety of therapies. | 25324352 | 2015 | |||||
Neurilemmoma
|
0.010 | GeneticVariation | BEFREE | A KRAS G12S mutation was also evident in one sporadic schwannoma. | 23190154 | 2013 |